Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are emerging glucose-lowering agents primarily used in managing diabetes and obesity. Recently, GLP-1 RAs have garnered attention for their cardiovascular benefits beyond glycaemic control in patients with type 2 diabetes, exhibiting patterns p...
Saved in:
| Main Authors: | Anastasia Shchendrygina, Amina Rakisheva, Ilya Giverts, Yasmin Rustamova, Anzhela Soloveva |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2024-09-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2024.05 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01) -
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01) -
Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action
by: Aleksandra Bykova, et al.
Published: (2024-10-01) -
Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology
by: Е. L. Nasonov, et al.
Published: (2024-04-01) -
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
by: Zhi Dong Zhou, et al.
Published: (2025-06-01)